checkAd

Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)

Relief Therapeutics Holding SA / Key word(s): Patent
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)

27-Apr-2022 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)

Notice of Allowance of Patent Application for Modified Release Orally Administered Amino Acid Formulations, Strengthens Proprietary Position in U.S. until 2036

Geneva, Switzerland, April 27, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that its wholly owned subsidiary, APR Applied Pharma Research SA ("APR"), has received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for Patent Application No. 15/303,121 entitled, "Modified Release Orally Administered Amino Acid Formulations."

The allowed claims cover certain PKU GOLIKE(R) formulations in APR's product line, intended to enhance the dietary management of patients living with phenylketonuria (PKU). The PKU GOLIKE(R) family of products are a phenylalanine-free food for special medical purposes (FSMP), comprising amino acid granules engineered with APR's Physiomimic Technology(TM), a modified-release amino acid technology that ensures a prolonged physiological absorption of the amino acids, while also masking their unpleasant taste, odor and aftertaste.

The USPTO issues a patent Notice of Allowance after it determines a patent should be granted upon completion of any outstanding administrative requirements. The patent resulting from this application will have an expiration date of no earlier than September 27, 2036. When issued, the patent will supplement APR's PKU GOLIKE(R) intellectual property portfolio, which currently includes U.S. Patent No. 10,500,180, which also expires no earlier than September 27, 2036.

Seite 1 von 4


Nachrichtenquelle: EQS Group AG
 |  257   |   |   

Schreibe Deinen Kommentar

Disclaimer

Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R) Relief Therapeutics Holding SA / Key word(s): Patent Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R) 27-Apr-2022 / 07:00 CET/CEST Release …

Nachrichten des Autors

300 Leser
210 Leser
158 Leser
152 Leser
151 Leser
126 Leser
122 Leser
114 Leser
107 Leser
107 Leser
479 Leser
384 Leser
365 Leser
320 Leser
310 Leser
301 Leser
300 Leser
288 Leser
284 Leser
274 Leser
2317 Leser
1023 Leser
723 Leser
693 Leser
642 Leser
636 Leser
549 Leser
505 Leser
488 Leser
479 Leser
2317 Leser
2237 Leser
2227 Leser
2225 Leser
2197 Leser
2108 Leser
1839 Leser
1797 Leser
1693 Leser
1629 Leser